Prevention of end-stage renal disease due to type 2 diabetes.

The prevalence of end-stage renal disease is increasing at an alarming rate. In 2000, chronic kidney failure developed in over 90,000 people in the United States; the current population of patients on dialysis numbers about 300,000, and 80,000 patients are living with transplanted kidneys. Both the prevalence and the incidence of end-stage renal disease are approximately twice what they were 10 years ago.1 Indeed, in 2000, the number of patients with newly diagnosed renal failure exceeded the number who died of any single type of cancer except lung cancer. Nephropathy due to type 2 diabetes accounts for almost all of . . .

[1]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[2]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[3]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[4]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[5]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[6]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[7]  N. Chaturvedi.  Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.

[8]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[9]  S. Ross,et al.  Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. , 2000, Kidney international.

[10]  J. Birkmeyer,et al.  The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors , 1999, Annals of Internal Medicine.

[11]  E. Ritz,et al.  Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.

[12]  M. Ravid,et al.  Use of Enalapril To Attenuate Decline in Renal Function in Normotensive, Normoalbuminuric Patients with Type 2 Diabetes Mellitus , 1998, Annals of Internal Medicine.

[13]  W. McClellan,et al.  Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.